All In Biotech

Drug Trial Radar · NCT06615375

A Human Challenge Study to Assess Protection of a Shigella Tetravalent Bioconjugate Vaccine

Phase 2b, Double-blind, Placebo-controlled Efficacy Challenge Study With the Shigella Tetravalent Bioconjugate Vaccine Shigella4V2

Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

97

Actual

Start

Nov 12, 2024

Primary completion

Apr 14, 2026

Study completion Sep 18, 2026

Sponsor

Lead sponsor
LimmaTech Biologics AGIndustry
Sponsor type
Industry
Collaborators
Emory University; Johns Hopkins Bloomberg School of Public Health; Children's Hospital Medical Center, Cincinnati
First posted
Sep 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

In this challenge study, the bioconjugate candidate vaccine Shigella4V2 will be tested for its ability to induce an immune response that protects healthy adult volunteers from infection with a wild-type Shigella sonnei strain compared to participants receiving placebo.

Conditions

  • Shigellosis

Interventions

  • Shigella4V2Biological

    Shigella4V2 is a tetravalent bioconjugate vaccine

  • PlaceboBiological

    Phosphate-buffered saline

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To demonstrate that the Shigella4V2 bioconjugate vaccine protects against shigellosis following challenge with the wild type S. sonnei 53G strain.Time frame: To be evaluated post-challenge during the inpatient period (Day 56 through Day 65) in vaccinees vs. placebo

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Hope Clinic of Emory University

    Atlanta, Georgia

  • Johns Hopkins Center for Immunization Research

    Baltimore, Maryland

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.